Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia

Summary

Despite knowledge of various inherited risk factors associated with venous thromboembolism (VTE), no definite cause can be found in about 50% of patients. The lack of an intermediate phenotype in VTE impedes the discovery of new familial risk factors. We set out to define an intermediate phenotype for VTE by performing global coagulation analyses in unexplained thrombophilic families. Families were selected through a proband with VTE but without one of the known thrombophilic defects and at least one 1st or two 2nd degree family members with VTE. Clinical data were collected using a standardized questionnaire. Blood samples were collected for overall haemostasis assays (i.e. thrombin generation time [TGT], endogenous thrombin potential [ETP], prothrombin fragment 1+2 [F1+2] and activated protein C-sensitivity ratio [APC-sr] and clot lysis time [CLT]). Data were analysed using logistic regression. Coagulation assays were performed in 353 individuals of whom 41 (12%) had a history of VTE; these belonged to 17 thrombophilic families. Of the tested variables only the ETP was associated with VTE (odds ratio [OR] 1.03 for each % increase, 95% confidence interval [CI] 1.01–1.05). However, the relatively low number of cases does not firmly exclude the other assays as candidate intermediate phenotypes for venous thrombosis. We found that an increased ETP may serve as an intermediate phenotype for VTE and may be used to discover novel inherited risk factors by genetic linkage analysis.

Keywords

Coagulation factors - deep venous thrombosis - familial thrombosis - hypercoagulability - venous thrombosis

• References

• 1 Heit JA, Phelps MA, Ward SA. et al. Familial segregation of venous thromboembolism. J Thromb Haemost 2004; 2: 731-736.
• 2 Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109: 369-384.
• 3 Larsen TB, Sorensen HT, Skytthe A. et al. Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. Epidemiology 2003; 14: 328-332.
• 4 Souto JC, Almasy L, Borrell M. et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 2000; 67: 1452-1459.
• 5 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
• 6 van der Meer FJ, Koster T, Vandenbroucke JP. et al. The Leiden Thrombophilia Study .(LETS). Thromb Haemost 1997; 78: 631-635.
• 7 Souto JC. Search for new thrombosis-related genes through intermediate phenotypes. Genetic and household effects. Pathophysiol Haemost Thromb 2002; 32: 338-340.
• 8 Mannucci PM, Tripodi A, Bottasso B. et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67: 200-202.
• 9 Bauer KA, Broekmans AW, Bertina RM. et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988; 71: 1418-1426.
• 10 O’Donnell J, Mumford AD, Manning RA. et al. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 2001; 115: 687-691.
• 11 Zoller B, Garcia de Frutos P, Hillarp A. et al. Thrombophilia as a multigenic disease. Haematologica 1999; 84: 59-70.
• 12 Ariëns RA, de Lange M, Snieder H. et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 2002; 359: 667-671.
• 13 Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-138.
• 14 Rosing J, Tans G, Nicolaes GA. et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-238.
• 15 Rosing J, Middeldorp S, Curvers J. et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
• 16 de Visser MC, van Hylckama V, Tans G. et al. Determinants of the APTT- and ETP- based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-1494.
• 17 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-650.
• 18 Lisman T, de Groot PG, Meijers JC. et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-1105.
• 19 Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996; 143: 1257-1265.
• 20 Nicolaes GA, Thomassen MC, Tans G. et al. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38.
• 21 Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62: 1198-1211.
• 22 Hopper JL, Mathews JD. Extensions to multivariate normal models for pedigree analysis. Ann Hum Genet 1982; 46: 373-383.
• 23 Boehnke M, Lange K. Ascertainment and goodness of fit of variance component models for pedigree data. Prog Clin Biol Res 1984; 147: 173-192.
• 24 Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
• 25 Kyrle PA, Mannhalter C, Beguin S. et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-1291.
• 26 Soria JM, Almasy L, Souto JC. et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003; 101: 163-167.
• 27 Soria JM, Blangero J, Souto JC. et al. Identification of a large deletion and three novel mutations in exon 13 of the factor V gene in a Spanish family with normal factor V coagulant and anticoagulant properties. Hum Genet 2002; 111: 59-65.
• 28 Soria JM, Almasy L, Souto JC. et al. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet 2002; 70: 567-574.
• 29 Hasstedt SJ, Scott BT, Callas PW. et al. Genome scan of venous thrombosis in a pedigree with protein C deficiency. J Thromb Haemost 2004; 2: 868-873.
• 30 de Lange M, Snieder H, Ariëns RA. et al. The genetics of haemostasis: a twin study. Lancet 2001; 357: 101-105.
• 31 Wichers IM, Tanck MWT, Meijers JCM. et al. Determinants of the endogenous thrombin potential in a Dutch thrombophilic family. J Thromb Haemost. 2007 3 (Suppl 1): Abstract PW474.
• 32 Wichers IM, Gast MCW, Beijnen JH. et al. Comparison of protein profile analysis in patients with and without a history of venous thromboembolism: a pilot study. J Thromb Haemost. 2005 3 (Suppl 1): Abstract OR240.